Ifigenia Kostoglou Athanassiou | Immunology and Endocrinology | Research Excellence Award

Research Excellence Award

Ifigenia Kostoglou Athanassiou
Department of Endocrinology, Asklepeion General Hospital

Ifigenia Kostoglou Athanassiou
Affiliation Department of Endocrinology, Asklepeion General Hospital
Country Greece
Scopus ID 6701404681
Citations 1,186  citations by 56 documents
h-index 18
Subject Area Immunology and Endocrinology
Event International Environmental Scientists Award
ORCID
0000-0002-2029-8372

Ifigenia Kostoglou Athanassiou is a Greek endocrinologist affiliated with the Department of Endocrinology at Asklepeion General Hospital. Her scholarly profile demonstrates sustained contributions to endocrinology, autoimmune disorders, and metabolic disease research through peer-reviewed publications, clinical investigations, and interdisciplinary scientific engagement.[1] Her academic record reflects continuing involvement in endocrine and immunological research areas relevant to modern healthcare systems and translational medical science.[2]

Abstract

This academic article presents a structured overview of the scientific profile and research achievements of Ifigenia Kostoglou-Athanassiou. The article summarizes her institutional affiliation, scholarly metrics, research focus areas, and contributions to endocrine and immunological sciences. It additionally evaluates the relevance of her scientific work in the context of the International Environmental Scientists Award. The analysis incorporates bibliometric indicators, selected publications, and broader academic impact indicators associated with endocrinology and immune-related disorders.[1][3]

Keywords

Endocrinology; Immunology; Autoimmune Diseases; Metabolic Disorders; Clinical Research; Endocrine Science; Academic Recognition; Translational Medicine; Hormonal Disorders; Research Excellence Award

Introduction

Endocrinology and immunology remain central disciplines within contemporary medical research due to their influence on metabolic regulation, inflammatory disorders, and chronic disease management. Researchers operating at the intersection of these domains contribute substantially to diagnostic advancement and therapeutic innovation.[4] Ifigenia Kostoglou-Athanassiou has participated in scientific investigations concerning endocrine disorders and related immunological mechanisms, contributing to broader clinical understanding within these areas.[2]

Her publication profile and citation metrics indicate a sustained record of academic productivity. Through clinical and research activities at Asklepeion General Hospital, her work has addressed endocrine dysfunctions, autoimmune associations, and metabolic complications affecting patient health outcomes.[5]

Research Profile

Kostoglou-Athanassiou maintains an established academic presence within endocrine and immunological sciences. According to indexed bibliographic records, her scholarly output includes 56 documents and more than one thousand citations, with an h-index of 18.[1] These indicators demonstrate measurable research visibility and continued scholarly engagement within the international scientific community.

Her research interests encompass autoimmune endocrinopathies, metabolic dysfunctions, thyroid disease, inflammatory responses, and hormonal regulation. The integration of clinical practice with academic investigation has enabled the development of research perspectives grounded in evidence-based medicine and patient-centered endocrinology.[6]

Research Contributions

The scientific contributions of  Kostoglou-Athanassiou include investigations into endocrine autoimmune disorders, inflammatory markers, metabolic syndrome, and hormonal interactions affecting systemic physiology.[7] Her research activities have contributed to improved understanding of endocrine complications associated with chronic disease and immune-mediated conditions.

Several of her studies have focused on the relationship between endocrine signaling pathways and inflammatory responses, particularly in conditions involving thyroid dysfunction and metabolic abnormalities.[8] Such investigations are relevant to contemporary healthcare challenges involving obesity, diabetes, autoimmune pathology, and systemic inflammation.

Her publication record additionally reflects interdisciplinary scientific collaboration and participation in peer-reviewed medical literature. The continued dissemination of endocrine research findings through indexed journals has strengthened scientific dialogue concerning diagnostic methodologies and therapeutic approaches.[9]

Publications

The Scopus profile lists 10 documents associated with Susanta Mandal [1]. Indexed publications play an important role in academic visibility because they allow research outputs to be discovered, cited, and evaluated within international scholarly databases.

Research Impact

The research impact associated with Kostoglou-Athanassiou is reflected through citation performance, publication continuity, and interdisciplinary scientific relevance. Her work contributes to medical understanding within endocrinology and related immune-mediated conditions, supporting both clinical application and ongoing academic investigation.[1]

The integration of immunological concepts into endocrine research is increasingly important for addressing chronic metabolic disease and inflammatory disorders. Her academic contributions align with broader healthcare objectives involving evidence-based medicine, translational science, and improved patient care outcomes.[10]

Award Suitability

Ifigenia Kostoglou-Athanassiou demonstrates several characteristics commonly associated with recipients of international scientific recognition awards. These include sustained scholarly productivity, peer-reviewed publication output, measurable citation impact, and continued engagement in clinically relevant research domains.[3]

Her scientific profile aligns with the objectives of the International Environmental Scientists Award through interdisciplinary medical research addressing metabolic health, systemic inflammatory mechanisms, and chronic disease interactions relevant to public health and environmental influences on human physiology.[11]

Conclusion

Ifigenia Kostoglou-Athanassiou represents an established academic contributor within endocrinology and immunological medical research. Her scholarly record, institutional affiliation, citation performance, and interdisciplinary investigations collectively demonstrate continued participation in scientific advancement. The integration of endocrine and immune-related research themes within her work supports broader clinical and public health objectives associated with evidence-based medical science and translational healthcare research.[1][5]

Reference

  1. Elsevier. (n.d.). Scopus author details: Ifigenia Kostoglou-Athanassiou, Author ID 6701404681. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=6701404681
  2. Medicina Lithuania. (2025). Euthyroid Sick Syndrome as an Index of Prognosis in Severe COVID-19 Disease.
    https://doi.org/10.3390/medicina
  3. Review Article. Targeted Cellular Treatment of Systemic Lupus Erythematosus.
    https://doi.org/10.1016/j.autrev
  4. Academic Endocrinology Research Resources. Autoimmune and Metabolic Endocrine Disorders.
    https://www.endocrine.org/
  5. Life Journal. (2024). Vitamin D Levels as a Marker of Severe SARS-CoV-2 Infection.
    https://doi.org/10.3390/life

 

Mohamed Eltokhy | Immunology | Best Researcher Award

Mr Mohamed Eltokhy | Immunology | Best Researcher Award

MSc., PhD Candidate, TTUHSC, Egypt 

Mohamed Ashraf Eltokhy is an Assistant Lecturer at the Graduate School of Biomedical Sciences at Texas Tech University Health Sciences Center (TTUHSC) in Abilene, Texas, and a PhD student specializing in Immunotherapeutic & Biotechnology. With a strong background in pharmacy and microbiology, his research is focused on cancer therapeutics, particularly in developing novel anticancer agents and advancing drug discovery mechanisms. His goal is to contribute to more effective and safer cancer treatments. Mohamed is also the CEO of Neopurpose Therapeutics, where he focuses on strategic decision-making, business development, and customer acquisition.

Profile

Orcid

📚 Education

Mohamed holds a Bachelor of Science in Pharmaceutical Science from Misr International University (MIU) in Cairo, Egypt, where he graduated with honors. He completed his MSc in Microbiology & Immunology from Al-Azhar University, also in Cairo. Currently, he is pursuing a PhD at Texas Tech University Health Sciences Center, where he maintains an impressive GPA of 3.948.

🎓 Experience

Mohamed’s career combines academic teaching and hands-on research. He serves as an Assistant Lecturer at MIU in Cairo, where he teaches microbiology, immunology, and biochemistry courses. Additionally, he is a Guest Researcher at Leiden University in the Netherlands and has worked as a pharmacist and in pharmaceutical regulatory affairs in Egypt. His work in cancer therapeutics is complemented by his leadership role as CEO of Neopurpose Therapeutics.

🧬 Research Interests

His research interests primarily focus on cancer treatment, specifically the development of novel anticancer agents and their mechanistic studies. He is also exploring the use of 3D bioprinted tumor-on-chip models for drug discovery and the individualization of chemotherapy regimens. His work includes in vitro and in vivo screening of agents and the study of their safety and efficacy.

🏆 Awards

Mohamed’s dedication to research and academic excellence has been recognized with multiple awards, including the Texas Tech Accelerator Program Award in 2024 and a late-breaking poster presentation award at the AACR conference in 2024. He has also received accolades for his contributions to the Microbiology & Immunology department at MIU, including academic excellence awards in 2021 and 2022, as well as the Top-Ranked Graduation Award in 2015 for achieving the highest GPA.

📖 Publications Top Notes

Patel, B., Silwal, A., Eltokhy, M. A., Gaikwad, S., Curcic, M., Patel, J., & Prasad, S. (2024). Deciphering CD59: Unveiling Its Role in Immune Microenvironment and Prognostic Significance. Cancers, 16(21), 3699.
Link to article

Eltokhy, M.A., Saad, B.T., Eltayeb, W.N., et al. (2024). Metagenomic nanopore sequencing for exploring the nature of antimicrobial metabolites of Bacillus haynesii. AMB Express, 14, 52.
Link to article

Eltokhy, M.A., Saad, B.T., Eltayeb, W.N., et al. (2021). Exploring the Nature of the Antimicrobial Metabolites Produced by Paenibacillus ehimensis Soil Isolate MZ921932 Using a Metagenomic Nanopore Sequencing Coupled with LC-Mass Analysis. Journal of Antibiotics (MDPI).
Link to article

Eltokhy, M.A., Saad, B.T., Eltayeb, W.N., et al. (2021). A metagenomic nanopore sequence analysis combined with conventional screening and spectroscopic methods for deciphering the antimicrobial metabolites produced by Alcaligenes faecalis soil isolate MZ921504. Journal of Antibiotics (MDPI).
Link to article

Eassa HA, Eltokhy MA, Fayyaz HA, et al. (2020). Current Topical Strategies for Skin-Aging and Inflammaging Treatment: Science versus Fiction. Europe PMC.
Link to article

Conclusion

In conclusion, Mohamed Ashraf Eltokhy is a highly deserving candidate for the Best Researcher Award, given his consistent dedication to advancing cancer research and his ongoing contributions to drug discovery. His work holds immense potential for improving cancer treatments and diagnostics, and with further growth in bioinformatics and clinical research, his impact on the field will undoubtedly increase. His leadership in both academic and entrepreneurial settings reflects his commitment to translating research into real-world applications.